These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 14666637)
1. TV-image analysis based quantification of the proliferative activity and the apoptotic rate in thyroid tumors and thyroiditis. Biesterfeld S; Rickert D; Eichler S; Fürste K; Mrusek S; Alfer J Anticancer Res; 2003; 23(5b):4269-75. PubMed ID: 14666637 [TBL] [Abstract][Full Text] [Related]
2. Differential diagnosis of keratoacanthoma and squamous cell carcinoma of the epidermis by MIB-1 immunohistometry. Biesterfeld S; Josef J Anticancer Res; 2002; 22(5):3019-23. PubMed ID: 12530035 [TBL] [Abstract][Full Text] [Related]
3. MIB-1 immunohistometry of follicular adenoma and follicular carcinoma of the thyroid gland. Rickert D; Mittermayer C; Lindenfelser R; Biesterfeld S Anal Quant Cytol Histol; 2000 Jun; 22(3):229-34. PubMed ID: 10872040 [TBL] [Abstract][Full Text] [Related]
4. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653 [TBL] [Abstract][Full Text] [Related]
5. MIB-1 immunohistometry on Tru-cut biopsies in inflammatory and cirrhotic liver disease. Biesterfeld S; Hoffmann E Anal Quant Cytol Histol; 1998 Aug; 20(4):268-74. PubMed ID: 9739409 [TBL] [Abstract][Full Text] [Related]
6. CA 19-9 expression in subacute (de Quervain's) thyroiditis: an immunohistochemical study. Schmid KW; Ofner C; Ramsauer T; Hittmair A; Tötsch M; Ladurner D; Böcker W Mod Pathol; 1992 May; 5(3):268-72. PubMed ID: 1495932 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of proliferation potential in thyroid normo-/hypofunctioning and hyperfunctioning nodules. Cornianu M; Stan V; Lazăr E; Dema A; Golu I; Tăban S; Vlad M; Faur A; Vărcuş F; Babău F Rom J Morphol Embryol; 2011; 52(2):545-53. PubMed ID: 21655641 [TBL] [Abstract][Full Text] [Related]
8. CD117 expression in normal, neoplastic, inflammatory, and reactive lesions of the thyroid. Aydin O; Yildiz L; Kefeli M; Kandemir B Pathol Res Pract; 2008; 204(6):359-65. PubMed ID: 18337018 [TBL] [Abstract][Full Text] [Related]
9. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling. Murphy KM; Chen F; Clark DP Hum Pathol; 2008 Mar; 39(3):420-6. PubMed ID: 18261626 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. El Demellawy D; Nasr AL; Babay S; Alowami S Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015 [TBL] [Abstract][Full Text] [Related]
11. Apoptosis and proliferative activity in thyroid tumors. Yoshida A; Nakamura Y; Imada T; Asaga T; Shimizu A; Harada M Surg Today; 1999; 29(3):204-8. PubMed ID: 10192728 [TBL] [Abstract][Full Text] [Related]
12. Combined evaluation of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers. Sharma H; Sen S; Mathur M; Bahadur S; Singh N Head Neck; 2004 Aug; 26(8):733-40. PubMed ID: 15287041 [TBL] [Abstract][Full Text] [Related]
13. Presence of immunoreactive corticotropin releasing hormone in thyroid lesions. Scopa CD; Mastorakos G; Friedman TC; Melachrinou M; Merino MJ; Chrousos GP Am J Pathol; 1994 Nov; 145(5):1159-67. PubMed ID: 7977646 [TBL] [Abstract][Full Text] [Related]
15. Comparative topoisomerase IIa and ki 67 protein expression in papillary thyroid carcinoma based on tissue microarrays and image analysis. Manaios L; Tsiambas E; Alevizaki M; Karameris A; Alexopoulou D; Lambropoulou S; Moreas H; Kravvaritis C; Fotiades PP; Goula K; Patsouris E; Athanassiou AE; Koutras D; Katsilambros N J BUON; 2008; 13(4):537-41. PubMed ID: 19145676 [TBL] [Abstract][Full Text] [Related]
16. Enhanced cellular proliferative activity and cell death in chronic thyroiditis and thyroid papillary carcinoma. Okayasu I; Saegusa M; Fujiwara M; Hara Y; Rose NR J Cancer Res Clin Oncol; 1995; 121(12):746-52. PubMed ID: 7499446 [TBL] [Abstract][Full Text] [Related]
17. Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions. Letsas KP; Frangou-Lazaridis M; Skyrlas A; Tsatsoulis A; Malamou-Mitsi V Pathol Int; 2005 Nov; 55(11):694-702. PubMed ID: 16271081 [TBL] [Abstract][Full Text] [Related]
18. Proliferative markers in diagnosis of thyroid tumors: a comparative study of MIB-1 and topoisomerase II-a immunostaining. Ludvíková M; Holubec L; Ryska A; Topolcan O Anticancer Res; 2005; 25(3A):1835-40. PubMed ID: 16033110 [TBL] [Abstract][Full Text] [Related]
19. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553 [TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues. Possible relationship to lymph node metastasis. Galusca B; Dumollard JM; Chambonniere ML; Germain N; Prades JM; Péoc'h M; Estour B Anticancer Res; 2004; 24(3b):1993-7. PubMed ID: 15274390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]